Article
Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Cancer biomarkers : section A of Disease markers - 6 Feb 2018
Masetti Michele, Acquaviva Giorgia, Visani Michela, Tallini Giovanni, Fornelli Adele, Ragazzi Moira, Vasuri Francesco, Grifoni Daniela, Di Giacomo Simone, Fiorino Sirio, Lombardi Raffaele, Tuminati David, Ravaioli Matteo, Fabbri Carlo, Bacchi-Reggiani Maria Letizia, Pession Annalisa, Jovine Elio, de Biase Dario
Abstract excerpt
BACKGROUND: Pancreatic adenocarcinoma (PDAC) is one of the deadliest human malignancies. Although surgery is currently the only effective treatment for PDAC, most patients survive less than 20 months after tumor resection. OBJECTIVE: The primary goal was to investigate alterations in KRAS, TP53, SMAD4 and CDKN2A/p16 in tumors from patients with exceptionally long survival after surgery. METHODS: Tumors from 15...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.